Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin SSD for Overt Hepatic Encephalopathy
NCT03515044Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Sep 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifaximin in hepatic encephalopathy (HE), sponsored by Valeant Pharmaceuticals. Started Sep 2018; status: completed.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT03515044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03515044.